CRVS
Corvus Pharmaceuticals, Inc.
There isn't enough reported data to score CRVS yet.
CRVS Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
CRVS's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
CRVS PE Valuation
CRVS has no meaningful PE right now: it lost money over the past year.
CRVS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect CRVS's losses to grow, with revenue growing.
CRVS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.74 | -$0.16 |
| Q2 2026 | -$0.64 | +$0.42 |
| Q1 2026 | -$0.55 | +$0.48 |
| Q4 2025 | -$0.53 | +$0.49 |
| Q3 2025 | -$0.58 | +$0.34 |
| Q2 2025 | -$1.06 | -$0.62 |
| Q1 2025 | -$1.03 | -$0.52 |
| Q4 2024 | -$1.02 | -$0.46 |
CRVS is still losing money, but far less than before: $0.74 per share over the past year, against $1.63 at its worst in early 2020.
CRVS Quarterly Revenue
CRVS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$12.3M | -$2.7M |
| Q2 2026 | -$16M | -$10.1M |
| Q1 2026 | -$10.5M | -$2.2M |
| Q4 2023 | -$5.2M | +$2.4M |
| Q3 2023 | -$5.4M | +$1.8M |
| Q1 2023 | -$8.1M | -$1.7M |
| Q1 2022 | -$6.4M | +$2.4M |
| Q4 2020 | -$8.2M | +$308K |
CRVS has burned cash in almost every quarter: −$48M over the past year, against −$29M the year before.
CRVS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +120K shares |
| 1 year | +12% | +9.7M shares |
| 3 years | +89% | +43.5M shares |
| 5 years | +110% | +48.5M shares |
| Available history | +215% | +63.1M shares |
CRVS has 92M diluted shares, up 12% from a year ago.
CRVS Net Leverage
CRVS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CRVS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.3 | Neutral |
| Stochastic | 18.2 | Oversold |
CRVS's weekly RSI is 42 (neutral) and its Stochastic is 18 (oversold).
CRVS PE vs Healthcare Sector
| Metric | CRVS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CRVS has no meaningful PE right now: it lost money over the past year.
CRVS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.5 | 0.8% above |
| 20 week MA | $12.7 | 16% below |
| 50 week MA | $13.3 | 20% below |
| 100 week MA | $9.24 | 15% above |
| 200 week MA | $5.97 | 78% above |
CRVS's trend is mixed: it's above three of its five weekly moving averages, and 78% above its 200-week average.
CRVS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.43 | $3.88 | -12% |
| 2021 | $3.88 | $2.73 | -30% |
| 2022 | $2.73 | $0.83 | -70% |
| 2023 | $0.83 | $1.76 | +112% |
| 2024 | $1.76 | $5.21 | +196% |
| 2025 | $5.21 | $7.70 | +48% |
| 2026 YTD | $7.70 | $10.6 | +38% |
CRVS's yearly returns have swung widely, from +196% in 2024 to −70% in 2022. It's up 38% so far in 2026.